Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Raymond W. Cohen net worth and biography

Raymond Cohen Biography and Net Worth

Co-Founder, Chief Executive Officer and Director of Axonics

Mr. Cohen has served as CEO and member of the board of directors since co-founding Axonics in October 2013. Mr. Cohen is an accredited public company director with over 35 years of experience in leading medical device companies and serving as a board member at a number of private and publicly traded life science companies.

From 2010 to 2012, he served as CEO of Vessix Vascular, a venture capital-backed renal denervation company that was acquired by Boston Scientific in November 2012. Previously, Mr. Cohen spent nearly a decade as Chairman and CEO of Nasdaq-listed Cardiac Science Inc., which was ranked as the fourth-fastest growing company in the US in 2004. Currently, Mr. Cohen serves as the Chairman of the board of directors at BioLife Solutions (Nasdaq: BLFS – preservation media for regenerative medicine) and member of the board of directors at BioVentrix, Inc. (privately-held transcatheter ventricular restoration company).

From June 2013 to April 2020, he served as an independent director, Chair of the compensation committee and member of the audit and nominating committees of Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI – Oncology drugs). Mr. Cohen also previously served on the boards of two companies that successfully executed an exit transaction in 2017, Zurich-based LifeWatch (LIFE.SW), sold to Biotelemetry (Nasdaq: BEAT); and Colorado-based Syncroness, Inc. (privately-held contract engineering firm), sold to ALTEN Group, a multibillion-dollar French engineering services company.

What is Raymond W. Cohen's net worth?: The estimated net worth of Raymond W. Cohen is at least $13.40 million as of January 31st, 2024. Mr. Cohen owns 188,835 shares of Axonics stock worth more than $13,403,508 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Cohen may own. Additionally, Mr. Cohen receives an annual salary of $1,750,000.00 as Co-Founder, Chief Executive Officer and Director at Axonics. Learn More about Raymond W. Cohen's net worth.
How old is Raymond W. Cohen?: Mr. Cohen is currently 65 years old. There are 7 older executives and no younger executives at Axonics. Learn More on Raymond W. Cohen's age.
What is Raymond W. Cohen's salary?: As the Co-Founder, Chief Executive Officer and Director of Axonics, Inc., Mr. Cohen earns $1,750,000.00 per year. Learn More on Raymond W. Cohen's salary.
How do I contact Raymond W. Cohen?: The corporate mailing address for Mr. Cohen and other Axonics executives is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. Axonics can also be reached via phone at (949) 396-6322 and via email at [email protected]. Learn More on Raymond W. Cohen's contact information.
Has Raymond W. Cohen been buying or selling shares of Axonics?: Raymond W. Cohen has not been actively trading shares of Axonics within the last three months. Most recently, Raymond W. Cohen sold 35,161 shares of the business's stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $67.74, for a transaction totalling $2,381,806.14. Following the completion of the sale, the chief executive officer now directly owns 188,835 shares of the company's stock, valued at $12,791,682.90. Learn More on Raymond W. Cohen's trading history.
Who are Axonics' active insiders?: Axonics' insider roster includes Juliet Bakker (Director), Raymond Cohen (Co-Founder, Chief Executive Officer and Director), Danny Dearen (Insider), Alfred Ford, Jr. (Insider), Kari Keese (CFO), Jane Kiernan (Director), Esteban Lopez (Director), Robert Mcnamara (Director), Karen Noblett (Insider), Rinda Sama (COO), and John Woock (CMO). Learn More on Axonics' active insiders.
Are insiders buying or selling shares of Axonics?: During the last year, insiders at the sold shares 8 times. They sold a total of 92,797 shares worth more than $6,275,226.67. The most recent insider tranaction occured on October, 2nd when CFO Kari Leigh Keese sold 2,961 shares worth more than $205,523.01. Insiders at Axonics own 1.9% of the company. Learn More about insider trades at Axonics.
Information on this page was last updated on 10/2/2024.

Raymond W. Cohen Insider Trading History at Axonics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/31/2024	Sell	35,161	$67.74	$2,381,806.14	188,835
1/31/2023	Sell	22,904	$61.15	$1,400,579.60	168,713
1/13/2023	Sell	40,736	$65.94	$2,686,131.84	108,899
8/8/2022	Sell	44,000	$70.44	$3,099,360.00	149,635
3/29/2022	Sell	50,000	$60.00	$3,000,000.00
3/14/2022	Sell	50,000	$52.82	$2,641,000.00
2/3/2022	Sell	35,115	$48.25	$1,694,298.75
9/9/2021	Sell	50,000	$77.11	$3,855,500.00
6/8/2021	Sell	33,333	$60.00	$1,999,980.00	284,607
5/18/2021	Sell	32,833	$55.00	$1,805,815.00	317,940
5/10/2021	Sell	33,833	$53.74	$1,818,185.42	371,497
2/1/2021	Sell	13,627	$51.42	$700,700.34	436,389
1/26/2021	Sell	7,842	$53.58	$420,174.36	424,231
8/11/2020	Sell	25,000	$42.15	$1,053,750.00	425,425
7/15/2020	Sell	25,000	$39.25	$981,250.00	483,430
7/13/2020	Sell	25,000	$40.35	$1,008,750.00	517,258
3/16/2020	Sell	41,224	$20.97	$864,467.28	583,282
2/13/2020	Sell	10,000	$33.21	$332,100.00	552,058
1/13/2020	Sell	10,000	$31.98	$319,800.00	618,391
11/19/2019	Sell	75,000	$20.74	$1,555,500.00	608,391
8/6/2019	Buy	3,500	$30.41	$106,435.00

Raymond W. Cohen Buying and Selling Activity at Axonics

Axonics Company Overview

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Today's Range

Now: $70.98

$70.37

$71.05

50 Day Range

MA: $70.61

$69.66

$70.98

2 Week Range

Now: $70.98

$55.09

$71.05

Volume

4,233,300 shs

Average Volume

713,457 shs

Market Capitalization

$3.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Most People Are Dead Wrong.

From Brownstone Research | Ad

I call it my AI Retirement Playbook. I recommend you check it out now.

Raymond Cohen Biography and Net Worth

What is Raymond W. Cohen's net worth?

How old is Raymond W. Cohen?

What is Raymond W. Cohen's salary?

How do I contact Raymond W. Cohen?

Has Raymond W. Cohen been buying or selling shares of Axonics?

Who are Axonics' active insiders?

Are insiders buying or selling shares of Axonics?